Shionogi stock holds firm as Japanese pharma sector trades mixed
Published on 09/01/2026 at 22:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Shionogi stock (ISIN JP3347200002) is showing a stable performance as of September 1, 2026, with the company valued on European markets at about 14.82 in euros and a reported market capitalization of EUR 12.61 billion according to data compiled by a major financial portal.
Market mood around Shionogi
On September 1, 2026, Japanese equities were described as mixed, with key indices such as the Nikkei 225 slipping modestly as rising bond yields and higher crude oil prices weighed on sentiment, according to several market overviews. For investors in Shionogi stock, this means the share is trading against a backdrop of cautious risk appetite rather than a company-specific sell-off.
In the same data overview that lists Shionogi with a price of 14.82 euros, the stock is categorized in the drug manufacturers specialty and generic industry and aligned with a market capitalization of EUR 12.61 billion. That valuation range positions Shionogi among the larger mid-cap to lower large-cap healthcare names in Japan when translated to euro terms.
Recent performance and positioning
Recent quote information for Shionogi American depositary receipts shows a price of 9.12 in United States dollars on September 1, 2026, slightly higher on the day, indicating a small single-digit percent gain in overseas trading. Taken together with the 14.82-euro European quotation, investors can see that Shionogi stock is trading near the middle of its recent range rather than at an extreme high or low.
The same European price snapshot that shows the 14.82-euro level also reports the EUR 12.61 billion market capitalization, which allows an implied comparison versus peers: if a similar specialty pharmaceutical name with comparable revenues were valued at, for example, EUR 10 billion, Shionogi would currently trade at around 26 percent higher equity value, signaling that the market is prepared to ascribe a premium for its pipeline and established products.
Background and further Shionogi coverage
More articles and regulatory news about Shionogi can be found in the topic overview for the company, which provides additional detail on financial results, product developments and strategic updates.
Key products support the franchise
Shionogi generates a substantial portion of its revenue from prescription medicines in infectious diseases and other specialty areas, and its established flagship therapies provide recurring cash flows that underpin the current equity valuation in the double-digit billion euro range. Historical annual reports indicate that the company has previously recorded revenues in the hundreds of billions of yen, illustrating the scale at which it operates even though these specific past figures now serve only as historical reference points for investors.
Shionogi stock and investor view
As of September 1, 2026, Shionogi stock is quoted at about 14.82 euros on European markets and around 9.12 United States dollars for its depositary receipts, with a corresponding market capitalization of approximately EUR 12.61 billion. This price constellation places the stock in a valuation band that reflects both its mature product portfolio and expectations for pipeline progress, while the broader Japanese market environment remains mixed.
Shionogi stock at a glance
- Company: Shionogi Co., Ltd.
- ISIN: JP3347200002
- Ticker: 4507
- Trading venue: Tokyo Stock Exchange and foreign listings
- Price (as of September 1, 2026): 14.82 EUR (European listing) / 9.12 USD (ADR)
- Market capitalization: 12.61 billion EUR (as of September 1, 2026)
- Sector / Industry: Health care / Drug manufacturers specialty and generic
- Index membership: Major Japanese equity indices
